TPST Stock Summary and Trading Ideas (Tempest Therapeutics | NASDAQ:TPST)

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Tempest Therapeutics trades on the NASDAQ stock market under the symbol TPST.

As of January 26, 2026, TPST stock price was flat at $2.98 with 24,415 million shares trading.

TPST has a beta of 1.69, meaning it tends to be more sensitive to market movements. TPST has a correlation of 0.06 to the broad based SPY ETF.

TPST has a market cap of $14.68 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, TPST traded as high as $127.01 and as low as $2.21.

The top ETF exchange traded funds that TPST belongs to (by Net Assets): VTI, VXF, DCOR, DFAC.

TPST has underperformed the market in the last year with a return of -75.2%, while the SPY ETF gained +14.9%. In the last 3 month period, TPST fell short of the market, returning -71.1%, while SPY returned +3.5%. However, in the most recent 2 weeks TPST has outperformed the stock market by returning +3.1%, while SPY returned -0.1%.

TPST support price is $2.83 and resistance is $3.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TPST shares will trade within this expected range on the day.